Replies to post #424017 on Amarin Corp Plc (AMRN)

[Tatsumaki]

Nah. You only get one "+1" extension with the EMA and it has to be filed and approved in the initial 8 year data exclusivity window. The system is designed to stop drug companies from doing what you describe... issue endless minor indications to try and lock up exclusivity forever. They want generics on the market.